Press Releases

Sapreme Unveils its Proprietary Endosomal Escape Platform in Presentations at 16th Annual Meeting of Oligonucleotide Therapeutics Society

September 30, 2020
positive preclinical data on its proprietary endosomal escape platform in two presentations at the 16th Annual Meeting of the O...
Read more
Sapreme Unveils its Proprietary Endosomal Escape Platform in Presentations at 16th Annual Meeting of Oligonucleotide Therapeutics Society

Cristal Therapeutics announces a publication in 'Chemical Science' on CliCr® technology platform

September 29, 2020
Cristal Therapeutics announces a publication in 'Chemical Science' on CliCr® technology platform, comprising a new class of sup...
Read more
Cristal Therapeutics announces a publication in 'Chemical Science' on CliCr® technology platform

Oncology Drug Development in Practice (ODDP) March 24-26, 2021

September 25, 2020
Training Course - Amsterdam March 24-26, 2021 - Oncology Drug Development in Practice (ODDP) 2021 is a 3-day educational program designed for professionals in industry and academia who wish to acquire or exp...
Read more

Cristal Therapeutics Awarded Horizon 2020 Grant to Further Develop the CriPec® Nanomedicine Platform

July 02, 2020
Horizon 2020 INNOSUP grant allows the funding of a highly skilled and experienced researcher (Innovation Associate) to develop...
Read more
Cristal Therapeutics Awarded Horizon 2020 Grant to Further Develop the CriPec® Nanomedicine Platform

ISA Pharmaceuticals receives US Orphan-Drug Designation for ISA101b in HPV16-positive Cervical Cancer

July 01, 2020
Primes the immune system to attack cancer cells in HPV16-positive cancers
Read more
ISA Pharmaceuticals receives US Orphan-Drug Designation for ISA101b in HPV16-positive Cervical Cancer

ISA Pharmaceuticals Strengthens Strategic Immuno-Oncology Collaboration with Regeneron

June 17, 2020
ISA Pharmaceuticals and Regeneron
Read more

CATO SMS Signs Agreement with InteRNA to Facilitate Phase I Solid Tumor Trial

May 19, 2020
InteRNA and CATO SMS signed an agreement in which CATO SMS will conduct the Phase I clinical trial with microRNA mimic INT-1B3...
Read more
CATO SMS Signs Agreement with InteRNA to Facilitate Phase I Solid Tumor Trial

Cristal Therapeutics Publishes Positive Data on its CriPec® Nanomedicine Technology in Small

May 11, 2020
Small publication demonstrates that superior therapeutic profiles of CriPec® nanomedicines result from rational design
Read more
Cristal Therapeutics Publishes Positive Data on its CriPec® Nanomedicine Technology in Small

InteRNA Technologies Receives Regulatory Approval for Initiation of Phase I Clinical Trial of INT-1B3 in Patients with Advanced Solid Tumors

May 06, 2020
InteRNA Technologies Receives Regulatory Approval for Initiation of Phase I Clinical Trial of INT-1B3 in Patients with Advanced...
Read more
InteRNA Technologies Receives Regulatory Approval for Initiation of Phase I Clinical Trial of INT-1B3 in Patients with Advanced Solid Tumors

ISA Pharmaceuticals announces CervISA publication

March 19, 2020
Synergy between Synthetic Long Peptides (SLP®) immunotherapeutics and standard chemotherapy in late stage cancer including mean...
Read more
ISA Pharmaceuticals announces CervISA publication

Home > Press Releases

© 2020 Aglaia Oncology Funds | Privacy | Sitemap
Aglaia Oncology Funds